Argent BioPharma Limited
RGT.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -73.7% | -28.4% | 59.7% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 22.9% | 42.8% | 38.3% | 44.2% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -1,770% | -593.9% | -429.2% | -491.9% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -1,967.4% | -614.6% | -430% | -535.6% |
| EPS Diluted | -0.47 | -7.07 | -7.63 | -6.95 |
| % Growth | 93.4% | 7.3% | -9.8% | – |
| Operating Cash Flow | -£0 | £0 | £0 | £0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |